1
项与 IDH1 peptide vaccine (University Hospital Heidelberg) 相关的临床试验Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)
The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1) peptide vaccine targeting the IDH1R132H mutation (amino acid exchange from arginine to glutamine at position 132 of IDH1). The aim of this trial is to evaluate the safety and tolerability of and immune response to the IDH1 peptide vaccine in patients with IDH1R132H-mutated, WHO grade III-IV gliomas.
100 项与 IDH1 peptide vaccine (University Hospital Heidelberg) 相关的临床结果
100 项与 IDH1 peptide vaccine (University Hospital Heidelberg) 相关的转化医学
100 项与 IDH1 peptide vaccine (University Hospital Heidelberg) 相关的专利(医药)
100 项与 IDH1 peptide vaccine (University Hospital Heidelberg) 相关的药物交易